Strategic partnerships HIPRA’s recent collaboration with Accord Healthcare to make a protein-based COVID-19 vaccine available in the UK indicates a openness to tiered partnerships and co-distribution models. This suggests sales opportunities in joint commercialization, licensing, and regional market entry arrangements with distributors and contract manufacturers.

Animal health leadership With a Managing Director of Animal Health recently appointed and a strong focus on prevention vaccines for animals, HIPRA presents a compelling opportunity to upsell broad-spectrum animal health portfolios, including novel vaccines and diagnostics for livestock, pets, and aquaculture in regions with intensive farming.

In ovo and RHD focus HIPRA has demonstrated product differentiation through in ovo administration vaccines and the recombinant YURVAC RHD vaccine for rabbit hemorrhagic disease. Sales potential exists in premium poultry and small mammals vaccine markets, as well as breeding and hatchery segments seeking advanced delivery and disease control solutions.

End-to-end control The company’s model of controlling the entire value chain—from R&D to production and commercialization—combined with a global distribution network, enables scalable partnerships for regional manufacturing, co-development, and rapid deployment of new biologics in targeted territories.

Vaccines plus diagnostics HIPRA’s integrated offering of vaccines and advanced diagnostic services positions cross-sell opportunities with diagnostic solutions, laboratory services, and monitoring programs for animal and human health, appealing to institutional buyers seeking a unified prevention and surveillance ecosystem.